GLOBAL LIVER INSTITUTE
Global Liver Institute (GLI) proudly supports legislation (S. 1941) introduced by Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) aiming to implement a nationwide elimination program for the hepatitis C virus (HCV) in the United States.
Global Fatty Liver Day is on June 12 – There’s Still Time to Get Involved!
This edition features a 5-year update on the Financial Toxicity Tumor Board Model, highlighting how multidisciplinary collaboration can reduce financial barriers to care.
Kristin Hatcher, Director of our Pediatric and Rare Liver Diseases Program, joined global leaders and the GLI team at the EASL Congress this May to elevate the conversation around rare liver diseases.
Global health leaders call for urgent, integrated action on the rising rates of metabolic liver disease during a high-level policy event held on the sidelines of the 78th World Health Assembly and co-hosted by Global Liver Institute (GLI), the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD).
Leading health organizations, policymakers, and public health advocates will come together during the 78th World Health Assembly (WHA78) for a pivotal side event titled “Together for Better Liver Health – Strengthening Public Health Responses to Metabolic Disease”.
Chronic infection of the liver by hepatitis B virus (HBV) remains a significant public health concern in the U.S. and around the world, particularly among at-risk populations.
Key House authorizing committees are slated to kick off markups on their respective budget reconciliation instructions that will be combined into a single reconciliation bill.
The introduction of new, dedicated ICD-10 diagnosis codes for Fontan-associated conditions in the U.S. Centers for Medicare & Medicaid Services (CMS) FY 2026 IPPS Proposed Rule marks a significant step forward for patients who have undergone the Fontan procedure.
Global Liver Institute brings you key updates in liver cancer research and treatment.
I recently conducted a workshop titled: Advanced Strategies: Navigating Credible Research and Accessing Clinical Trial Opportunities, as part of GLI’s A4 ,program with a focus on clinical research participation.
On Friday, April 4, 2025, the U.S. Centers for Medicare and Medicaid (CMS) released the 2026 Medicare Advantage and Part D Final Rule and decided not to finalize the proposed rule to extend obesity treatment coverage to Medicare and Medicaid beneficiaries.
